Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,203 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use.
Ito S, Otsuki S, Ohsawa H, Hirano A, Kazuno H, Yamashita S, Egami K, Shibata Y, Yamamiya I, Yamashita F, Kodama Y, Funabashi K, Kazuno H, Komori T, Suzuki S, Sootome H, Hirai H, Sagara T. Ito S, et al. ACS Med Chem Lett. 2023 Mar 10;14(4):396-404. doi: 10.1021/acsmedchemlett.3c00006. eCollection 2023 Apr 13. ACS Med Chem Lett. 2023. PMID: 37077386 Free PMC article.
TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X.
Ito K, Nishio M, Kato M, Murakami H, Aoyagi Y, Ohe Y, Okayama T, Hashimoto A, Ohsawa H, Tanaka G, Nonoshita K, Ito S, Matsuo K, Miyadera K. Ito K, et al. Among authors: ito s. Mol Cancer Ther. 2019 May;18(5):920-928. doi: 10.1158/1535-7163.MCT-18-0645. Epub 2019 Mar 14. Mol Cancer Ther. 2019. PMID: 30872380
Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K, Miura A, Sagara T, Ito S, Ohsawa H, Otsuki S, Funabashi K, Yashiro M, Matsuo K, Yonekura K, Hirai H. Sootome H, et al. Among authors: ito k, ito s. Cancer Res. 2020 Nov 15;80(22):4986-4997. doi: 10.1158/0008-5472.CAN-19-2568. Epub 2020 Sep 24. Cancer Res. 2020. PMID: 32973082
Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2).
Day JEH, Berdini V, Castro J, Chessari G, Davies TG, Day PJ, St Denis JD, Fujiwara H, Fukaya S, Hamlett CCF, Hearn K, Hiscock SD, Holvey RS, Ito S, Kandola N, Kodama Y, Liebeschuetz JW, Martins V, Matsuo K, Mortenson PN, Muench S, Nakatsuru Y, Ochiiwa H, Palmer N, Peakman T, Price A, Reader M, Rees DC, Rich SJ, Shah A, Shibata Y, Smyth T, Twigg DG, Wallis NG, Williams G, Wilsher NE, Woodhead A, Shimamura T, Johnson CN. Day JEH, et al. Among authors: ito s. J Med Chem. 2024 Mar 28;67(6):4655-4675. doi: 10.1021/acs.jmedchem.3c02118. Epub 2024 Mar 10. J Med Chem. 2024. PMID: 38462716
2-Cyclohexylcarbonylbenzimidazoles as potent, orally available and brain-penetrable opioid receptor-like 1 (ORL1) antagonists.
Kobayashi K, Uchiyama M, Takahashi H, Kawamoto H, Ito S, Yoshizumi T, Nakashima H, Kato T, Shimizu A, Yamamoto I, Asai M, Miyazoe H, Ohno A, Hirayama M, Ozaki S, Tani T, Ishii Y, Tanaka T, Mochidome T, Tadano K, Fukuroda T, Ohta H, Okamoto O. Kobayashi K, et al. Among authors: ito s. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3096-9. doi: 10.1016/j.bmcl.2009.04.023. Epub 2009 Apr 11. Bioorg Med Chem Lett. 2009. PMID: 19394217
.: Kobayashi, K.; Kato, T.; Yamamoto, I.; Shimizu, A.; Mizutani, S.; Asai, M.; Kawamoto, H.; Ito, S.; Yoshizumi, T.; Hirayama, M.; Ozaki, S.; Ohta, H.; Okamoto, O. ...
.: Kobayashi, K.; Kato, T.; Yamamoto, I.; Shimizu, A.; Mizutani, S.; Asai, M.; Kawamoto, H.; Ito, S.; Yoshizumi, T.; Hi …
Optimization of benzimidazole series as opioid receptor-like 1 (ORL1) antagonists: SAR study directed toward improvement of selectivity over hERG activity.
Kobayashi K, Kato T, Yamamoto I, Shimizu A, Mizutani S, Asai M, Kawamoto H, Ito S, Yoshizumi T, Hirayama M, Ozaki S, Ohta H, Okamoto O. Kobayashi K, et al. Among authors: ito s. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3100-3. doi: 10.1016/j.bmcl.2009.04.022. Epub 2009 Apr 11. Bioorg Med Chem Lett. 2009. PMID: 19398200
Discovery and in vitro and in vivo profiles of 4-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide as novel class of an orally active metabotropic glutamate receptor 1 (mGluR1) antagonist.
Satoh A, Nagatomi Y, Hirata Y, Ito S, Suzuki G, Kimura T, Maehara S, Hikichi H, Satow A, Hata M, Ohta H, Kawamoto H. Satoh A, et al. Among authors: ito s. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5464-8. doi: 10.1016/j.bmcl.2009.07.097. Epub 2009 Jul 23. Bioorg Med Chem Lett. 2009. PMID: 19674894
Discovery of novel diarylketoxime derivatives as selective and orally active melanin-concentrating hormone 1 receptor antagonists.
Suzuki T, Kameda M, Ando M, Miyazoe H, Sekino E, Ito S, Masutani K, Kamijo K, Takezawa A, Moriya M, Ito M, Ito J, Nakase K, Matsushita H, Ishihara A, Takenaga N, Tokita S, Kanatani A, Sato N, Fukami T. Suzuki T, et al. Among authors: ito j, ito s, ito m. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5339-45. doi: 10.1016/j.bmcl.2009.07.132. Epub 2009 Aug 6. Bioorg Med Chem Lett. 2009. PMID: 19683441
Novel ORL1-selective antagonists with oral bioavailability and brain penetrability.
Okamoto O, Kobayashi K, Kawamoto H, Ito S, Yoshizumi T, Yamamoto I, Hashimoto M, Shimizu A, Takahashi H, Ishii Y, Ozaki S, Ohta H. Okamoto O, et al. Among authors: ito s. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3282-5. doi: 10.1016/j.bmcl.2008.04.037. Epub 2008 Apr 28. Bioorg Med Chem Lett. 2008. PMID: 18448337
9,203 results